Outcomes of prescription opioid dose escalation for chronic pain: results from a prospective cohort study
- PMID: 31985590
- DOI: 10.1097/j.pain.0000000000001817
Outcomes of prescription opioid dose escalation for chronic pain: results from a prospective cohort study
Abstract
The use of long-term opioid therapy for chronic pain remains common, yet data on long-term outcomes, especially after dose escalation, are sparse. This study examined potential benefits and harms associated with prescription opioid dose escalation. Participants from 2 institutions were enrolled in a 2-year prospective cohort study. All participants (n = 517) had a musculoskeletal pain diagnosis and were receiving a stable dose of long-term opioid therapy at baseline. Participants completed self-report measures of pain, disability, depression, and potential adverse effects at baseline and every 6 months for 2 years. We reviewed electronic health record data weekly to identify episodes of prescription opioid dose escalation; participants who had increases in their dose were seen for additional research visits within 1 month of dose escalation. Over 2 years, 19.5% of participants had prescription opioid dose increases. After controlling for covariates, there were no significant changes on any variable after dose escalation. Of those with a dose increase, 3% experienced a clinically meaningful improvement in pain after dose escalation. Participants in the entire sample had small improvements in pain intensity, depressive symptoms, medication-related side effects, and lower risk for prescription opioid misuse during the study period. Sexual functioning worsened over time. There were no significant changes in the full sample on pain disability, sleep functioning, or experiencing a fall. In summary, patients prescribed stable doses of long-term opioid therapy may demonstrate small changes in key pain-related outcomes over time, but prescription opioid dose escalation status is unrelated to clinical outcomes.
Similar articles
-
Prospective Investigation of Factors Associated with Prescription Opioid Dose Escalation among Patients in Integrated Health Systems.J Gen Intern Med. 2020 Dec;35(Suppl 3):895-902. doi: 10.1007/s11606-020-06250-x. Epub 2020 Nov 3. J Gen Intern Med. 2020. PMID: 33145684 Free PMC article.
-
Dose escalation during the first year of long-term opioid therapy for chronic pain.Pain Med. 2015 Apr;16(4):733-44. doi: 10.1111/pme.12634. Epub 2014 Dec 19. Pain Med. 2015. PMID: 25529548 Free PMC article.
-
Higher Prescription Opioid Dose is Associated With Worse Patient-Reported Pain Outcomes and More Health Care Utilization.J Pain. 2017 Apr;18(4):437-445. doi: 10.1016/j.jpain.2016.12.004. Epub 2016 Dec 18. J Pain. 2017. PMID: 27993558 Free PMC article.
-
Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety.Pain Med. 2015 Oct;16 Suppl 1:S3-8. doi: 10.1111/pme.12904. Epub 2015 Sep 11. Pain Med. 2015. PMID: 26360931 Review.
-
Disrupting the downward spiral of chronic pain and opioid addiction with mindfulness-oriented recovery enhancement: a review of clinical outcomes and neurocognitive targets.J Pain Palliat Care Pharmacother. 2014 Jun;28(2):122-9. doi: 10.3109/15360288.2014.911791. Epub 2014 May 20. J Pain Palliat Care Pharmacother. 2014. PMID: 24845547 Review.
Cited by 7 articles
-
Associations of opioid prescription dose and discontinuation with risk of substance-related morbidity in long-term opioid therapy.Pain. 2022 Apr 1;163(4):e588-e595. doi: 10.1097/j.pain.0000000000002415. Pain. 2022. PMID: 34326295
-
Associations of Pain Numeric Rating Scale Scores Collected during Usual Care with Research Administered Patient Reported Pain Outcomes.Pain Med. 2021 Oct 8;22(10):2235-2241. doi: 10.1093/pm/pnab110. Pain Med. 2021. PMID: 33749760 Free PMC article.
-
Association Between Opioid Dose Reduction Against Patients' Wishes and Change in Pain Severity.J Gen Intern Med. 2020 Dec;35(Suppl 3):910-917. doi: 10.1007/s11606-020-06294-z. Epub 2020 Nov 3. J Gen Intern Med. 2020. PMID: 33145690 Free PMC article.
-
Pharmacological Chaperones Attenuate the Development of Opioid Tolerance.Int J Mol Sci. 2020 Oct 13;21(20):7536. doi: 10.3390/ijms21207536. Int J Mol Sci. 2020. PMID: 33066035 Free PMC article.
-
Mindfulness-oriented recovery enhancement reduces opioid dose in primary care by strengthening autonomic regulation during meditation.Am Psychol. 2020 Sep;75(6):840-852. doi: 10.1037/amp0000638. Am Psychol. 2020. PMID: 32915027 Free PMC article. Clinical Trial.
References
-
- Buelow A, Haggard R, Gatchel RJ. Additional validation of the Pain Medication Questionnaire in a heterogenous sample of chronic pain patients. Pain Pract 2009;9:428–34.
-
- Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality improvement project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Inter Med 1998;158:1789–95.
-
- Busse JW, Wang L, Kamaleldin M, Craigie S, Riva JJ, Montoya L, Mulla SM, Lopes LC, Vogel N, Chen E, Kirmayr K, De Oliveira K, Olivieri L, Kaushal A, Chaparro LE, Oyberman I, Agarwal A, Couban R, Tsoi L, Lam T, Vandvik PO, Hsu S, Bala MM, Schandelmaier S, Scheidecker A, Ebrahim S, Ashoorion V, Rehman Y, Hong PJ, Ross S, Johnston BC, Kunz R, Sun X, Buckley N, Sessler DI, Guyatt GH. Opioids for chronic noncancer pain: a systematic review and meta-analysis. JAMA 2018;320:2448–60.
-
- Chasens ER, Ratcliffe SJ, Weaver TE. Development of the FOSQ-10: a short version of the functional outcomes of sleep questionnaire. Sleep 2009;32:915–19.
-
- Chen L, Sein M, Vo T, Amhmed S, Zhang Y, Hilaire KS, Houghton M, Mao J. Clinical interpretation of opioid tolerance versus opioid-induced hyperalgesia. J Opioid Manag 2014;10:383–93.
Publication types
MeSH terms
Substances
Grant support
LinkOut - more resources
Full Text Sources
Medical